March 10 (Reuters) - PMGC Holdings Inc ELAB.O:
NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1
NORTHSTRIVE BIOSCIENCES : SCHEDULED A PRE-IND MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APRIL 23, 2025
Source text: nGNX7B0PkG
Further company coverage: ELAB.O
((Reuters.Briefs@thomsonreuters.com;))